Similarly, for the third CDK4/6 inhibiting agent, abemaciclib, phase III clinical trials proved the increase in the PFS when using abemaciclib in the progressive and in the first-line treatment of advanced HR+/HER-2 negative breast cancer postmenopausal females (25, 26). The gene discussed is ERBB2; the disease is breast carcinoma.